Genexine Inc. (KOSDAQ: 095700), an innovative biotechnology company developing a novel long-acting form of recombinant human growh hormone (rhGH), known as GX-H9, for growth hormone deficiency (GHD) patients, today announced that Dr. Keyoung, CEO of Genexine, is scheduled to present at the 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE) on Nov 19, 2016, at the Tokyo International Forum. This presentation will include EU/KR Phase 2 interim data for both pediatric and adult GHD clinical trials in a podium session.
Event: The 50th Annual Meeting of the Japanese Society for Pediatric Endocrinology (JSPE)
Date: November 16th– November 20th
Location: Tokyo International Forum
▶About GX-H9
GX-H9, being co-developed with Handok under a strategic partnership, is a next-generation, long-acting growth hormone consisting of genetically fused rhGH with Genexine’s proprietary hybrid Fc (hyFc) platform technology which revealed the possibility of both weekly and twice-monthly administration.
▶About JSPE 2016
Founded in 1967, the Japanese Society for Pediatric Endocrinology (JSPE) has been leading the field of pediatric endocrinology and pediatric diabetes in Japan. JSPE has over 1,300 clinicians and researchers, who have specialized in pediatric endocrinology and diabetes. JSPE has established clinical practice guidelines for the most of the endocrinological disorders. Moreover, JSPE members have achieved substantial contributions to elucidating the mechanisms of a variety of endocrinological disorders utilizing cutting-edge techniques for molecular analyses such as next generation sequencing.
▶ About Genexine:
Genexine, Inc. is a leading biotherapeutics company focused on immuno-oncology and metabolic/autoimmune diseases. Genexine has robust pipelines in clinical and pre-clinical stages based on long-acting Fc fusion technology and therapeutic DNA technology. In the clinical stage, Genexine has GX-H9 (hGH-hyFc) for both adult and pediatric hGH deficiencies, currently in phase II trials in the EU and Korea after the completion of EU Phase I. GX-188E therapeutic DNA vaccine for HPV-associated diseases is in Phase II in Europe and Korea. GX-I7 is genetically fused Interleukin-7 with hybrid Fc platform technology, currently developed as a treatment of lymphopenia, cancer, and infectious diseases. Founded in 1999, Genexine, located in Korea Bio Park, consists of about 140 employees and half of them are scientists with MSc or Ph.D. Genexine was listed on KOSDAQ (095700) in 2009.